Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial

Wenying Yang, Zhaojun Yang, Jing Zhao, Hai Lu, Tianhong Luo, Wenying Yang, Zhaojun Yang, Jing Zhao, Hai Lu, Tianhong Luo

Abstract

Background: A large proportion of patients with T2DM in China do not meet accepted HbA1c targets despite the availability of guidelines that describe a treatment pathway for achieving glycemic control. The aim of this study is to identify the fasting plasma glucose (FPG) target that will provide the highest control rate of HbA1c <7 % in Chinese patients with T2DM treated with an insulin glargine-based regimen as an adjunct to an established OAD regimen. This information will support improvements in diabetes care management in China.

Methods: Approximately 934 men and women aged ≥18 to ≤65 years with poorly controlled T2DM will be enrolled and randomized to one of three FPG target groups; ≤5.6 mmol/L, ≤6.1 mmol/L, or ≤7.0 mmol/L. They will be initiated on daily insulin glargine (Lantus®) in addition to their usual OAD regimen for 24 weeks. Patients will self-monitor fasting blood glucose (SM-FBG), and the study physician will titrate the basal insulin dose according to the SM-FBG results. In addition, HbA1c and safety will be recorded. We plan to statistically derive the optimal FPG target for an HbA1c of <7 %.

Discussion: In China, treatment strategies that would achieve an optimum balance between glycemic control (as per HbA1c) and hypoglycemia are imperative to ensure improvements in the management of T2DM. Furthermore, elucidating the contribution of FPG to HbA1c in Chinese patients with T2DM and identifying a predictable relationship between FPG and HbA1c would be a valuable tool for patient self-management of diabetes.

Trial registration: NCT02545842 . Registered on 8 September 2015.

Keywords: Fasting plasma glucose; Oral antidiabetic drugs; Self-monitor fasting blood glucose; Type 2 diabetes mellitus; glycated hemoglobin.

Figures

Fig. 1
Fig. 1
Schematic flow diagram of the study design. FPG fasting plasma glucose, OAD oral antihyperglycemic drug
Fig. 2
Fig. 2
Schedule of visits, treatment, and data collection
Fig. 3
Fig. 3
Titration Committee detailed information

References

    1. Colagiuri S, Kent J, Kainu T, et al. Rising to the challenge. Preventing and managing type 2 diabetes. Report of the WISH Diabetes Forum 2015. 2015
    1. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33:811–831. doi: 10.1007/s40273-015-0268-9.
    1. International Diabetes Federation . IDF diabetes atlas. 6. Brussels, Belgium: International Diabetes Federation; 2014.
    1. Aguiree F, Brown A, Cho NH, et al. IDF diabetes atlas. Brussels: International Diabetes Federation; 2013.
    1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–1101. doi: 10.1056/NEJMoa0908292.
    1. Ji LN, Zhang PH, Weng JP, et al. Basal insulin treatment in patients with type 2 diabetes uncontrolled on oral antihyperglycemic agents: ORBIT study in China. Diabetes. 2015;64:A235–A382. doi: 10.2337/db14-1042.
    1. Chen Y, Liu L, Gu L, Babineaux S, Colclough H, Curtis B. Glycemic control in Chinese patients with type 2 diabetes mellitus receiving oral antihyperglycemic medication-only or insulin-only treatment: a cross-sectional survey. Diabetes Ther. 2015;6(2):197–211. doi: 10.1007/s13300-015-0114-2.
    1. American Diabetes Association Classification and diagnosis of diabetes. Diabetes Care. 2015;38 Suppl:S8–S16. doi: 10.2337/dc15-S005.
    1. International Diabetes Federation Guideline Development Group Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1–52. doi: 10.1016/j.diabres.2012.10.001.
    1. American Diabetes Association Standards of medical care in diabetes—2014. Diabetes Care. 2014;37 Suppl 1:S14–S80. doi: 10.2337/dc14-S014.
    1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):1–87. doi: 10.4158/EP15672.GLSUPPL.
    1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–480. doi: 10.1016/S2213-8587(14)70057-9.
    1. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006;12:RA130–RA147.
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. Ramachandran A, Riddle MC, Kabali C, et al. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012;35:749–753. doi: 10.2337/dc11-1918.
    1. Tanenberg R, Stewart J, Zisman A. Glycemia optimization treatment (GOT): glycemic control and rate of severe hypoglycemia for 5 different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM) Diabetologia. 2006;49:601–602.
    1. Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(8):638–652. doi: 10.1016/S2213-8587(15)00097-2.
    1. LaSall JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113:152–162.
    1. Blonde L, Merilainen M, Karwe V, et al. Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE™ study. Diabetes Obes Metab. 2009;11:623–631. doi: 10.1111/j.1463-1326.2009.01060.x.
    1. Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):51–63. doi: 10.1111/nyas.12098.
    1. Yabe D, Seino Y, Fukushima M, Seino S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:36. doi: 10.1007/s11892-015-0602-9.
    1. Gujral UP, Pradeepa R, Weber MB, Narayan V, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281(1):51–63. doi: 10.1111/j.1749-6632.2012.06838.x.
    1. Chinese Diabetes Society. Chinese type 2 diabetes mellitus treatment guidelines: 2013 edition. 2014;6:447–498
    1. Yang W, Lv X, Li Q, et al. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 2012;28:533–541. doi: 10.1185/03007995.2012.671764.
    1. Arnolds S, Heise T, Flacke F, et al. Common standards of basal insulin titration in type 2 diabetes. J Diabetes Sci Technol. 2013;7:771–788. doi: 10.1177/193229681300700323.
    1. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013;13:602. doi: 10.1186/1471-2458-13-602.
    1. Tsai ST, Pathan F, Ji L, et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3:208–216. doi: 10.1111/j.1753-0407.2011.00137.x.
    1. Handelsman Y, Mechanick J, Blonde L, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17:1–53. doi: 10.4158/EP.17.S2.1.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться